NUCLIDIUM, NorthStar Medical partner to secure copper-67 supply for theranostics

NUCLIDIUM AG and NorthStar Medical have formed a long-term partnership to produce and supply copper-67, a beta-emitting radioisotope, to support NUCLIDIUM’s radiotheranostic pipeline for prostate and breast cancers.

• NUCLIDIUM plans to initiate multiple therapeutic studies using Cu-67 for metastatic castration-resistant prostate cancer (NU101) and metastatic breast cancer (NU201) in the coming months.
• NorthStar produces Cu-67 via electron accelerator technology with integrated manufacturing infrastructure designed to scale radiopharmaceutical programs.
• These radiotheranostics remain investigational; safety and efficacy will be evaluated in upcoming clinical trials.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.